Cambium Bio Secures A$10.85 Million Funding Package
Filed with ASX · · 4 pages · English
Earlier from Cambium Bio
- Proposed issue of securities - CMB
- Notice of ceasing to be a substantial holder
- Change in Substantial Holding
- Update - Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
Later from Cambium Bio
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
- Notification of cessation of securities - CMB
- Date of AGM and Closing Date for Director Nominations
- Corporate Presentation - September 2026
- Notice of Annual General Meeting and Proxy form
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio